Fortress Biotech, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2025

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

10. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:


		December 31,			December 31,
($ in thousands)		2025			2024
Accounts payable		$	14,238		$	31,636
Accrued expenses:
Professional fees			1,055			3,147
Salaries, bonus and related benefits			7,880			6,596
Research and development			277			8,509
Accrued royalties payable			1,805			1,374
Accrued coupon and rebates			16,547			6,200
Return reserve			2,177			3,124
Other¹			3,146			4,915
Total accounts payable and accrued expenses		$	47,125		$	65,501

Note 1: Other as of December 31, 2025 and 2024 includes approximately $1.3 million of accrued consideration for the Mustang Asset Purchase Agreement with uBriGene, see Note 3.